Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Rituximab +/- Chemotherapy in R/R B-cell NHL
NCT02953509Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of magrolimab in B-cell non-Hodgkin lymphoma (10 cohorts), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Dose-limiting Toxicities at 28 days, Percentage of Participants Experiencing Treatment Emergent Adverse Events up to 7.2 years and 1 more. Started Nov 2016; status: terminated.
02
Drugs
magrolimab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02953509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953509.